Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

2.40
+0.04001.69%
Pre-market: 2.420.0192+0.80%07:13 EDT
Volume:2.03M
Turnover:4.85M
Market Cap:432.21M
PE:-5.94
High:2.45
Open:2.39
Low:2.33
Close:2.36
52wk High:6.88
52wk Low:1.61
Shares:180.09M
Float Shares:132.00M
Volume Ratio:0.80
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:2.60
PE(LYR):-5.69

Loading ...

Compass Therapeutics reports Phase 1 CTX-8371 data showing 33% ORR at top doses

Reuters
·
May 22

Compass Therapeutics to Participate in Upcoming May Investor Events

GlobeNewswire
·
May 12

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Tenax Therapeutics (TENX) and Compass Therapeutics (CMPX)

TIPRANKS
·
May 10

Compass Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

Guggenheim Remains a Buy on Compass Therapeutics (CMPX)

TIPRANKS
·
May 06

Compass Therapeutics Inc. : Leerink Partners Cuts Target Price to $4 From $11

THOMSON REUTERS
·
May 06

Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained

TIPRANKS
·
May 06

H.C. Wainwright Keeps Their Buy Rating on Compass Therapeutics (CMPX)

TIPRANKS
·
May 05

Compass Therapeutics Q1 EPS $(0.10), Inline

Benzinga Earnings
·
May 05

Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs

Reuters
·
May 05

Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Dow Jones
·
May 05

Compass Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 29

Compass Therapeutics Price Target Maintained With a $10.00/Share by Citizens

Dow Jones
·
Apr 28

Compass Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 28

Compass Therapeutics publishes 2025 annual report

Reuters
·
Apr 28

Compass Therapeutics price target lowered to $6 from $12 at Stifel

TIPRANKS
·
Apr 28

Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies

TIPRANKS
·
Apr 28

Leerink says Compass data supports path forward for tovecimig in 2L BTC

TIPRANKS
·
Apr 28

This Biotech Stock Is Down 61%. How a Cancer Trial Was Ruined by Its Own Design. -- Barrons.com

Dow Jones
·
Apr 28

LifeSci Capital Sticks to Its Buy Rating for Compass Therapeutics (CMPX)

TIPRANKS
·
Apr 27